Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2021
Reporting Period: Third fiscal quarter ended September 30, 2021
Context: The filing serves to announce the Company's financial results for the third quarter of 2021 via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended September 30, 2021.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release titled "Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights," but the specific content of the commentary, guidance, or outlook is not present in the provided text.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q3 2021 revenue, net loss, and cash position figures.
- Verify the "Corporate Highlights" mentioned in the press release title for updates on clinical trials or product development.
- Check for any forward-looking guidance or updated financial projections provided in the full press release.
- Confirm the Company's cash runway and burn rate as disclosed in the full financial results.